Clinician’s Guide to Prevention and Treatment of OsteoporosisFelicia Cosman, R. Lindsay, Suzanne M. Jan de Beur et al.|Osteoporosis International|2014Cited by 4.1k
Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for OsteoporosisSteven R. Cummings, Susan Randall, E. Michael Lewiecki et al.|Journal of Bone and Mineral Research|2016Cited by 162
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled PeriodAnthony A. Portale, Karl Insogna, Nobuaki Ito et al.|Calcified Tissue International|2019Cited by 160
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extensionKarine Briot, Erik A. Imel, Anthony A. Portale et al.|RMD Open|2021Cited by 72
High-throughput Molecular Analysis of Pseudohypoparathyroidism 1b Patients Reveals Novel Genetic and Epigenetic DefectsJennifer A. Danzig, Michael A. Levine, Dong Li et al.|The Journal of Clinical Endocrinology & Metabolism|2021Cited by 26